effective

passionate

determined

relentless

innovative

NBCC

bold

energized
A Message from The President

Relentless. Passionate. Determined. Energized. Innovative. Bold. All these words describe NBCC and our advocacy. But one word best describes our impact — Effective. We get things done.

For nearly 30 years, NBCC has led the effort to end breast cancer through action and advocacy. Our unique approach and advocate expertise, our focus and tenacity, has resulted in significant progress through the years.

We have asked the difficult questions, challenged the status quo, and forced change. After decades of work at the national, state, and local levels, NBCC is the undisputed leader in identifying and directing the policy, scientific, clinical, and research tools needed to end breast cancer.

As you’ll see in the pages ahead, in 2018, NBCC continued to build and strengthen some of our hallmark programs. From our intensive advocacy training programs and focused legislative goals, to our unique scientific and research undertakings like the Artemis Project and DNA.Land, we continue to expand our audience and increase our impact.

At NBCC, we will do whatever it takes to end breast cancer. Whether this means taking on the status quo in questioning long-held perceptions, we go where the science leads us – not where public opinion, headlines, or hype do. We’re not afraid. Even if it’s not popular.

As we fight this battle, we face continued obstacles, but we won’t be deterred. In the following pages, you can read more about our successes, and our plans to build on them.

We need your continued support, advocacy, and commitment if we are to reach our ambitious but achievable goal — a world without breast cancer.

Fran Visco
President, National Breast Cancer Coalition
The Advocate Voice:
Training Advocate Leaders in Science and Policy

NBCC provides the highest quality advocacy training, tools, and education to enable breast cancer survivors and other advocates to take leadership roles in clinical and scientific decision making that affects breast cancer research, healthcare, and public policy.

Understanding scientific concepts and processes at a level to make a real difference takes a great deal of work, dedication, training, and time. NBCC advocates are willing to make that commitment and acquire the education and skills they need through NBCC’s Center for Advocacy Training, the umbrella program for our education and training curriculum. We give advocates and the public the needed tools to understand and translate complex medical information and to partner with scientists in designing and conducting research, including clinical trials.
An energized, committed and passionate group of NBCC leaders came together for our 2018 Advocate Leadership Summit in Arlington, VA, on April 28 – 30 for networking, training and education in research and policy.

The preconference program began with a Project LEAD® Workshop: “Early Dissemination of Cells That Become Lethal Metastasis.” The Summit featured fascinating plenary sessions on the progress of the Artemis Project, advocacy in the current political climate, the ethical issues surrounding cancer treatments, as well as an armchair discussion on the impact of DoD-funded research, and a Q&A session with Dr. Dennis Slamon. There were nine skill-building workshops on topics such as how to participate effectively in a scientific peer review and ramp up critical appraisal skills, to policies affecting access to health care, understanding genomics and breast cancer, and the NBCC initiative Campaign Vote Breast Cancer.

In addition to a substantive program, the Summit provided plenty of opportunities for networking and connecting with advocates from across the country. Advocates were also able to interact directly with the speakers during the Advocate-Speaker Meet Ups. These meet-ups provided opportunities for dialogue with speakers in a smaller, more casual setting.

Advocates were enthusiastic with the Summit programming. They valued the variety of the skill-building workshops, as well as the opportunity to converse with scientists in an intimate setting. The 2018 Summit, with its focus on bold advocacy, made many attendees eager for opportunities to put the skills they learned into practice.
Project LEAD® Institute educates advocates to understand complex medical information, the nuances of research methodology and the unique role advocates play in influencing the research agenda. Advocates learn about cancer biology, genetics, DNA, RNA, proteins, epidemiology, clinical trial research design and much more. This world renowned six-day program enables attendees to develop skills in critical appraisal so that they are able to ask relevant questions and explain the significance of medical and health information to their communities.

NBCC hosted another successful Project LEAD® Institute in La Jolla, California July 22–27. A diverse class of 43 advocates gathered for a week of intense, dedicated study. The class included participants from 18 different states and international advocate leaders from Armenia, Australia, and Mexico.

Graduates of the Project LEAD® Institute play critical roles in programs such as the Department of Defense (DoD) Breast Cancer Research Program (BCRP), clinical trials and research programs domestically and abroad.

Advanced Project LEAD®

The Advanced Project LEAD® program further trains LEAD graduates who have a deep interest in and propensity for taking leadership roles in breast cancer research advocacy as NBCC representatives. In 2018, Advanced LEAD® advocates engaged in an in-depth, intensive program over two days, that delved into how research and evidence are used in evaluating drug and device effectiveness in the treatment of breast cancer. Advocates also got a closer look at FDA approval processes and examined case studies about how genetic tests are evaluated. The program culminated in the development of a policy paper outline addressing how evidence is used in developing the statutory language found in regulations and other legislation.

In the fall, advocates completed the Advanced Project LEAD® proposal project, the development of a scientific proposal and presentation. These advocates will join the class of other Advanced LEAD® advocates to participate with NBCC on important research projects.
Continuing Education for Project LEAD® Graduates

Project LEAD® graduates continue their science education through the Project LEAD® Continuing Education Program.

LEADcasts provide access to online webinars that are presented by Project LEAD® faculty and other notable experts on current topics in breast cancer research. These webinars take place several times a year and are open to all advocates who have graduated from a Project LEAD® course. Below is a list of highlights from the 2018 LEADcasts:

- **Immunotherapy and CAR-T: A Decade of Progress in the Clinic**, Premal Patel, MD, PhD, Senior Vice President, Early Clinical Development, Juno Therapeutics, Inc.
- **Tumor Draining Lymph Nodes and Biologic Behavior**, Peter Lee, MD, Billy and Audrey L. Wilder Endowed Professor and Chair Cancer Immunotherapeutics & Tumor Immunology (CITI), City of Hope Comprehensive Cancer Center
- **Surrogate Endpoints in Clinical Trials**, Vinay Prasad, MD, MPH, Associate Professor of Medicine at Oregon Health and Science University
- **The Normal Breast and Its Development**, Susan Love, MD, Dr. Susan Love Research Foundation
- **The Immune System and Tumor Dormancy: Can we prevent lethal disease?**, Cyrus Ghajar, PhD, Fred Hutchinson Cancer Research Center

In December, 75 Project LEAD® graduates gathered prior to the San Antonio Breast Cancer Symposium to participate in NBCC’s annual Project LEAD® Advanced Topics Session. This year’s program featured a presentation by Dr. Keith Knutson of the Mayo Clinic, who discussed his work on breast cancer vaccine trials – both the progress on a preventative vaccine and research on vaccines that could prevent breast cancer recurrence. Attendees also heard a presentation from Dr. Nicholas McAndrew of the UCLA David Geffen School of Medicine on the science behind, and his research into, CDK 4/6 inhibitors.

Online Center for Advocacy Training

NBCC’s Online Advocacy Training Center is a resource for advocates around the world to hear presentations from leaders in the breast cancer field, including presenters from NBCC’s Project LEAD® courses, Advanced Topics sessions, and Advocacy Summits. In 2018, NBCC expanded this resource to include more videos and LEADcasts so advocates could access these thought-provoking and educational conversations.

Team Leader Training

In March 2018, NBCC selected 22 breast cancer advocates from around the country to come to Washington, DC for an intensive training and development in grassroots advocacy, the federal legislative process, the NBCC legislative and public policy agenda, and lobbying techniques. Following training and preparation, advocates participated in Capitol Hill meetings with Congressional staff to discuss NBCC’s legislative and public policy agenda.
The Artemis Project®

NBCC’s research work focuses on the Artemis Project®, an advocate-led, innovative, mission-driven approach of strategic summits, catalytic workshops, action plans and collaborative efforts of various stakeholders, focusing on two areas: Primary Prevention and Prevention of Metastasis.

In March, NBCC held annual meetings on both topics. These meetings included 35 participants comprised of advocates and scientists with expertise ranging from immunology, biophysics, and genetics, to molecular biology, and clinical oncology.

Primary Prevention

Important progress has been made in the critical activities needed to develop and test a preventive vaccine. In 2018, the vaccine development plan was presented to the FDA and received positive feedback. The project now moves to the next critical steps leading to a Phase I safety trial. Overall, the Artemis Project continues to advance the concept that a breast cancer prevention vaccine is feasible, and its development continues to be pioneered by Artemis.

Prevention of Metastasis

At the 2018 meeting, the group discussed how data would be best used to identify targets for preventing lethal disease and risk reduction. Participants in the Artemis Project are continuously reevaluating the state of the sciences to ensure that alternatives, or additional opportunities to prevent breast cancer and end deaths are being considered, and appropriately incorporated into the goals of the Artemis Project. To this end, the participants discussed the following topics during the meeting:

- Designing an Anti-Metastasis Clinical Trial
- Grand-Challenge: Disseminated Tumor Cells In Situ
- Vaccine Against New-Antigens to Prevent Metastasis
DNA.Land

*DNA.Land* asks individuals to submit results of genetic tests done through various companies that perform genome testing on saliva and answer a clinical questionnaire specific to breast cancer. The goal is to develop a database resource to help determine why some individuals with breast cancer recur. By the end of 2018, over 25,000 people had completed the clinical questionnaire.

A summary report from the 2018 Artemis Project® meetings is available online: [http://www.breastcancerdeadline2020.org/about-the-deadline/artemis-project.html](http://www.breastcancerdeadline2020.org/about-the-deadline/artemis-project.html)

**Advocate Influence**

National Breast Cancer Coalition Board Members, Project LEAD® graduates, advocates and members continue to be active on national and international committees dedicated to furthering breast cancer research. Highlights include the Department of Defense Breast Cancer Research Program (DOD BCRP) Integration Panel, Love/Avon Army of Women Steering Committee, Advisory Council of the Agency for Healthcare Research and Quality, and a number of steering committees and data safety monitoring committees of clinical trials for new therapies. And, NBCC President, Fran Visco, served as a member of Translational Research in Oncology’s (TRIO) Board of Directors and also on the Governance Board for the Institute for Clinical and Economic Review. For a full list, please visit [www.deadline2020.org/NationalCommittees](http://www.deadline2020.org/NationalCommittees).

Our leaders and advocates continue to push for partnerships and collaboration, especially when it comes to clinical trial design and oversight. Over the past 12 months, the results of two important clinical trials were reported and NBCC was a collaborator in both of them. NBCC advocates gave input into trial design, sat on steering committees and had the first ever lay advocate participate as a member of a data safety monitoring board.
Our advocacy efforts have transformed the way breast cancer is seen and heard and have made NBCC one of the most respected organizations on Capitol Hill. With our annual lobby days and national action network, NBCC called on its network of hundreds of groups and tens of thousands of grassroots advocates to focus on NBCC’s legislative and public policy priorities. Each year, NBCC’s Board of Directors establish NBCC’s legislative and public policy priorities. Two of NBCC’s top 2018 legislative and public policy priorities were:

**DoD Breast Cancer Research Program**

The [Department of Defense Breast Cancer Research Program](#) (DOD BCRP) was established as a direct result of NBCC’s leadership in the breast cancer community. The annual Congressional renewal process is grueling and complex, but NBCC’s efforts ensure annual funding for the program remains a top priority. In 2018, NBCC effectively advocated for another $130 million in breast cancer research from the DOD BCRP. One of the reasons NBCC values the DOD BCRP is because it accepts and reviews innovative and even unconventional proposals that may provide important breast cancer research breakthroughs. To date, funding totals more than $3.6 billion for research. NBCC and its advocates involvement with the DOD BCRP is also about participation, which is a crucial piece of the program. NBCC breast cancer advocates are members and participate in peer and programmatic review.

The full list of NBCC’s 2018 and current priorities can be found at [breastcancerdeadline2020.org](http://breastcancerdeadline2020.org).

**H.R. 6114 — Metastatic Breast Cancer Access to Care Act**

NBCC continued to focus efforts on protecting quality care for breast cancer patients. H.R. 6114, one of NBCC’s top legislative priorities, is a bill to waive the waiting periods for Medicare and Social Security Disability Insurance for eligible individuals diagnosed with metastatic breast cancer. The legislation was introduced in June and, thanks to the amazing work by NBCC advocates, ended the 115th Congress with 96 cosponsors.
End Breast Cancer: Vote!

In 2018, NBCC launched the End Breast Cancer: Vote! campaign. The campaign asked everyone who cares about breast cancer policy to vote in the mid-term elections and ask their elected officials to support NBCC’s platform. Components included NBCC’s public policy platform, a voter pledge form, and a toolkit for advocates. NBCC used a microsite, social media posts and ads to publicize the campaign, NBCC’s public policy platform and encourage candidates to sign on to support our platform.

National Action Network

Our grassroots leadership and National Action Network are key components of NBCC’s advocacy success. Made up of organizations and individuals across the country, this far-reaching grassroots network continues to empower women and men who share a sense of urgency about ending breast cancer. NBCC educates, informs and energizes this network throughout the year.

NBCC’s Annual Lobby Day was held May 1, where over 200 meetings occurred with members and congressional staff on Capitol Hill. Over 50 lobby day meetings were held in March as part of Team Leader Training. We emailed action alerts to our network asking advocates to contact specific legislators via phone, email, Facebook and Twitter. Additionally, NBCC field staff hosted leadership strategy conference calls each month.
Outreach and Media

NBCC’s website continues to be a unique resource for newly diagnosed women and their families, as well as others interested in patient-centered, evidence-based information. It is the place for breast cancer patients to get the full story on major controversies in breast cancer. The website provides a variety of thoughtful and informative resources that explain NBCC’s position and encourages women to learn the truth about breast cancer in order to make informed decisions regarding their health care.

NBCC maintains an active social media presence to communicate directly with our audience. Sites such as Facebook, Twitter and YouTube allow NBCC to provide important information to new and existing audiences. This continues to be an evolving area of importance to engage advocates and the general public about NBCC priorities.

International media outlets such as the New York Times, CNN, NPR, and USA Today have contacted NBCC for statements and reactions on important developments in breast cancer and health care. In September, The New York Times published a letter to the editor from NBCC President Fran Visco entitled, “Top Cancer Researcher Fails to Disclose Financial Ties in Major Research Journals” in response to their article about a well-known oncologist and researcher who failed to disclose millions of dollars in payments from pharmaceutical companies.

In December, The Cancer Letter published a guest editorial written by Fran, where she discussed recent news in the breast cancer research world and highlighted the role NBCC advocates play in addressing these issues. Trained, educated advocates need to shine a light on the problems that impede progress and they must figure out the solutions. They should be setting the research agenda, collaborating on research generation and conduct, and helping set rules to foster transparency and eliminate conflicts of interest which threaten further progress toward our mission of ending breast cancer.

Other Media highlights include:

- Statements written on the TAILORx Trial results, Direct to Consumer Genetic Testing and H.R. 6114 Metastatic Breast Cancer Access to Care Act

- NBCC and the LA Cabaret event were mentioned in outlets Including People, US Magazine, Daily Mail, Access Online, Entertainment Today and Orlando Sentinel

- NBCC was mentioned in a story broadcast by ABC-WUSA Channel 9, Swim Marathon to fight Breast Cancer

- NBCC President Fran Visco was quoted in an article in US Army Magazine, Investing for Breakthroughs
Les Girls

NBCC’s 18th annual Les Girls Cabaret was held in October at the Avalon Theater in Hollywood. Every year the event captivates attendees with an unforgettable evening of laughter and song. We honored Dr. Armando Guiliano, the Co-Director of the Saul and Joyce Brandman Breast Center at Cedars-Sinai with the 2018 Les Girls Leadership Award, for his dedication to saving lives and commitment to breast cancer. The award was presented by Julia Louis-Dreyfus. Our spectacular celebrity entertainers such as Sharon Lawrence, Lea Thompson and Steven Weber performed and title sponsor is Clinical helped raise over $400,000 for NBCC’s program and important work.

Laura Avril and Marylinn Minor were presented with awards by our gracious host Tamara Tunie. Guests enjoyed an incredible performance by We’ McDonald, The Voice Season 11, contestant.

NYC Women with Balls®

The second annual NYC Women with Balls® bowling fundraiser was held at the Bowlmor Lanes in Times Square in May, hosted by Liane Martins Linder, Chairman of NBCC’s Board of Trustees. The event brought together like-minded, compassionate and energetic women and men to raise money, bowl and have fun — all for the mission of ending breast cancer.
Your Dollars at Work

Expenses 2018

- CATALYTIC RESEARCH 21%
- PUBLIC INFORMATION 10%
- FUNDRAISING 10%
- MANAGEMENT & GENERAL 7%
- GRASSROOTS, ETC 7%
- OTHER PROGRAMS 1%
- PUBLIC POLICY 13%
- EDUCATION & TRAINING 30%

Assets 2018

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash &amp; Cash Equivalents</td>
<td>$770,246</td>
</tr>
<tr>
<td>Accounts Receivables</td>
<td>$895,564</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>$102,467</td>
</tr>
<tr>
<td>Net Property &amp; Equipment</td>
<td>$184,781</td>
</tr>
<tr>
<td>Deposits</td>
<td>$57,134</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$2,061,326</td>
</tr>
<tr>
<td>LIABILITIES</td>
<td>$429,177</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td>$1,632,149</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES &amp; ASSETS</strong></td>
<td>$2,061,326</td>
</tr>
</tbody>
</table>

2018 Public Support & Other Revenue

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2%</strong> Other revenue</td>
<td>$54,753</td>
</tr>
<tr>
<td>Corporation &amp; Foundations</td>
<td>11%</td>
</tr>
<tr>
<td>Restricted Grants</td>
<td>26%</td>
</tr>
<tr>
<td>Special Events</td>
<td>43%</td>
</tr>
<tr>
<td>Individuals</td>
<td>18%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporation &amp; Foundations</td>
<td>$311,730</td>
</tr>
<tr>
<td>Restricted Grants</td>
<td>$768,497</td>
</tr>
<tr>
<td>Special Events</td>
<td>$1,254,458</td>
</tr>
<tr>
<td>Individuals</td>
<td>$536,272</td>
</tr>
</tbody>
</table>
2018 President’s Council

Edite Abolins†
Geoff Adamson
Madeline and Stephen Anbinder
Bonnie Anderson
Carla and Michael Angelo
Susan and Robert Appleton
Sue E. Baebler
Kathy M. Ball
Annette and Avram Bar-Cohen
Robert Bazell
Carol A. Beagan
Lori and Bob Beck
Gerry Bernardi and Joe Keenan
Dr. Susan V. Bershad
Laurel Bezanson
Dr. Isabelle T. Bisceglio
Carmella Bocchino
Steve B. Bonner
Daniel Bonoff
Douglas Braff
Donna Brogan
Deborah C. Brown
Shirley H. Brown
Bruce Brown
Mr. and Mrs. George R. Buckley
Alec Call and Bryan Johns
Maureen Calloway Carnevale and Richard Carnevale
Christine B. and Delburn Carpenter
Richard Cassese
Carol and Richard Chadakoff
Jan R. Cloyde
Mary Ellen Colten†
Victoria G. Cooke
Emily and John M. Costigan
Elaine M. Coughlin
Dr. Judith C. & David Craver
Susan M. Dacks
Doreen and Robert Davis
Rutger Dequay
Dr. Judy Dering and Frank Calzone
Karen Di Nunzio
Betty J. Dietrich
Elaine M. Dornig
Donna Duncan
Kate Dwyer
Dale and Harry Eastman
Dr. Stephen J. Elledge
Dr. Matthew and Rosana Ellis
Beth Emery
Ileana and Irvin Fagin
Sherri Ades Falchuk
Phyllis Fern
Joseph Flanagan
Alan B. Fleischer
Dr. Silvia C. Formenti
Elizabeth and Richard Frank
Meryl French
Patricia L. Freysinger
Jeffrey C. Golden
Dorian S. Goldman and Marvin Israelow
Katja Goldman and Michael Sonnenfeld
Lloyd and Victoria Goldman
Sherry Goldman
Stephanie and Josh Goldstine
Nancy Goler
Pennelope Goodfriend
George T. Grant
Gabrielle and Rob Greenberg
Amy Gross
Kathleen and Arthur Harris
Pat Haugen
Robert E. Haydon
Susan R. Hester
Ira Hillman and Jeremy Barber
Judi J. Hirshfield-Bartek and Elmer Bartek
Cathy S. Holloway
Joanne M. Howes
Marie A. Iandoli
Rosemary and Alfred W. Iversen
Nicole Jadue
Harris Jaffe
Linda A. Jbara
Cary Jones
Jean L. Jorgenson
Elaine Kadets
Natalie R. Kase
Neil Katcher
John A. Kay
Hugh Kendrick
Diana Wendt and Hugh Kendrick
Ethel Klein
Richard Kossik
Janet C. Kossman
Robert K. Kretzman
Summer Krywucki
Dr. Leona Laskin
Tracy E. Leduc
Paula Levine and Dr. Bernard Beitzman
Karen and Franklin Lewkowitz
Susan F. and James Lindsay
Caroline and James Losty
Diane B. Lotti
Dr. Susan M. Love
Hannah Low
Wanda A. Lucas
Lawrence B. Ludwig
Dr. Ngina Lythcott and Byllye Avery
Nicolette Maloney
Carol Matyka
Mary Matyka
Michele May and Dr. David R. Walt
Musa and Tom Mayer
Dorrie McCaffrey
Joseph P. McCarthy
Carolyn C. McCormick
Jacqueline McMullen
Catherine M. Meek and Al Earle
Beth Sieroty Meltzer
Rose Mennella
Christine M. Millen
Stephen and Viv Moeller
Gayle A. Nobbs
Melinda S. and Scott Nordeng
Christine K. and Dermod Norton
John Noss
Shelby Notkin
Norma and Dr. Norman Nutman
Jeanne Olson
Randy Ososky
Greg Otto
Michele Rakoff and Alan Sieroty
Richard B. Rickard
Pamela Romanow
Marlyn Rosskam
Rosemary Rosso, JD
Dr. Linda and Ken Rothweiler
Nancy A. and James Ryan
Helen Schiff and Richard Congress
Marlyn Schiffer
Gail and Dr. Steven Shak
Edward A. Shapiro
Lauren Shuler Donner
Russell Silverman
Joy A. Simha and Vasu Chari
Carly Simon
Arleen F. Sorkin and Christopher Lloyd
Dr. Maureen A. Strafford
Sharon Sutter
Nicki and Harold Tanner
Jeffrey and Dina Tranen
Amy Upchurch
Fran M. Visco and Arthur N. Brandolph
Madeline and Dr. Richard Wachter
Elizabeth Wade
Carol and Terry Wall
Pamela West
Jerry L. Worden
Ann C. Yahner
Dr. Stanley E. Zeitz

† Deceased
2018 Donors

$250,000 & Above
Celgene
Dorian S. Goldman and
Marvin Israelow
Joyce and Irving Goldman
Family Foundation
Katja Goldman and
Michael Sonnenfeldt
Lloyd and Victoria Goldman
Carol and Terry Wall
Vance Wall Foundation

$100,000-$249,000
Alec Call and Bryan Johns
iS CLINICAL by INNOVATIVE SKINCARE
Musa and Tom Mayer
National Philanthropic Trust

$50,000-$99,999
Anonymous
Patient Centered Outcomes Research Institute
Pfizer Inc.
Revolon, Inc.
Translational Research in Oncology-US, Inc. (TRIO-US)

$25,000-$49,999
The Allergan Foundation
Genomic Health, Inc.
The Horn Foundation
Judges & Lawyers Breast Cancer Alert
Longchamp USA, Inc.
Nicole Maloney
The Maloney Family Foundation
Novartis Oncology
Skadden, Arps, Slate, Meagher & Flom LLP
Steve Tisch Family Foundation
Sullivan & Cromwell LLP
Williams and Connolly LLP

$10,000-$24,999
Arnold & Porter LLP
Avalon Apparel, LLC
CARE Advocates
Citigroup Global Market, Inc.
Cozen O'Connor
The Carole & Robert Daly Charitable Foundation
Deloitte & Touche LLP
Kathleen Dwyer
Eisai Inc.
Dr. Stephen J. Elledge
Dr. Armando Giuliano
Google
Jones Day
KPMG, LLP
Linklaters LLP
Mellam Family Foundation
Merck & Co., Inc.
Milbank, Tweed, Hadley & McCloy LLP
Peter Morton
Jonathan Moss
Moss Foundation
Otica, Inc.
Proskauer Rose LLP
Michele Rakoff and Alan Sieroty
Dr. Linda and Ken Rothweiler
Arleen F. Sorkin and
Christopher Lloyd
Fern and Lenard Tessler
Deanna van Gestel
Ann C. Yahner

$5,000-$9,999
Bill Bernbach Foundation
Debbie and James Burrows
Nancy and Dwayne Burton
Cedar Sinai Breast Center
Krishna Daly
Beth Emery
Dr. Silvia C. Formenti
Patricia L. Freysinger
David Geffen Foundation
Penelope Goodfriend
Julia Hall
Kathleen and Arthur Harris

Hearst Magazines
Barry Hirsch
Lonnie L. Israel
Susan K. Johns
Blake T. Johns and Brittany Shaw
Jones Lang Lasalle
Suzanne and Ric Kayne
Liane M. and Luca Lindner
Susan F. and James E. Lindsay
Michele May and Dr. David R. Walt
Christine M. Millen
Christine K. and Dermod Norton
John Noss
Paul Hastings LLP
Margaret Perenchio
The Relief Foundation
Saul Ewing, LLP
Katherine K. Tobin
Elaine Trebek-Kares
Fran M. Visco and
Arthur N. Brandolph
Pamela West
Ronald Witt

$2,500-$4,999
Susanna Lachs Adler and Dean Adler
Debbie and Mark Attanasio
Janet F. and George Buckley
Christine B. and Delburn Carpenter
Dr. Judy Dering and Frank Calzone
Donna Duncan
Elizabeth S. and Richard Frank Genentech, Inc.
Kristin Girouard
Glickfield Family Foundation
Sherry Goldman
Ira Hillman and Jeremy Barber
Judi J. Hirshfield-Bartek and Elmer Bartek
Marina Maher
Catherine M. Meek and Al Earle
Lauren Mitran
Plastek Industries, Inc.
Egberto Ramirez
Helen Schiff and Richard Congress
Andrew D. Shepard

We have done our best to review these lists. If anything appears incorrect, please accept our apologies and contact NBCC's Development Office at 202-973-0573 or info@breastcancerdeadline2020.org.
2018 Board of Directors

ABCD: After Breast Cancer Diagnosis
Bonnie Anderson (D), Ginny Finn (A)

Alamo Breast Cancer Foundation
Jerry Worden (D), Beth Emery (A)

American Association of Breast Care Professionals
Rhonda Turner (D), Gretchen Walton (A)

Annie Appleseed Project
Ann Fonfa (D), Rasheedah Ahmad (A)

Breast Cancer Care and Research Fund
Michele Rakoff (D), Michele Atlan (A)

CARE Advocates Network
Carol Matyka (D), Karen Poliseno (A)

Cedar Valley Cancer Committee: Beyond Pink TEAM
Christine Carpenter (D), Lori Seawel (A)

Cedars Sinai Breast Center
Sherry Goldman (D), Sylvia Estrada (A)

Delaware Breast Cancer Coalition, Inc.
Vicky Cooke (D)

Dr. Susan Love Research Foundation
Judi Hirshfield-Bartek (D)

Georgia Breast Cancer Coalition Fund
Sheryl Cherico (D)

Linda Creed Breast Cancer Foundation
Donna Duncan (D), Linda Camerota (A)

Louisiana Coalition of African American Breast Cancer Survivors
Julia Bradford Moore (D), Eunice Lavigne (A)

Metropolitan Washington, DC Chapter of NBCC
Wanda Lucas (D)

Michigan Breast Cancer Coalition
Rose Marie Sitko (D), Jeanne Deneweth (A)

Minnesota Breast Cancer Coalition
Christine Norton (D), Pat Haugen (A)

National Breast Cancer Coalition
Frances M. Visco (D)

Nueva Vida
Astrid Jimenez, Esq. (D), Gloria Elliott (A)

SHARE
Ivis Febus-Sampayo (D), Helen Schiff (A)

St. Louis Breast Cancer Coalition
Mary Lynn Faunda Donovan (D)
Sheila McGlown (A)

Virginia Breast Cancer Foundation
Susan Siegel (D), Katy Sawyer (A)

Young Survival Coalition
Joy Simha (D)
2018 Board of Trustees

Alec R. Call | Los Angeles, CA
Co-founder, Executive Vice President and COO for Science of Skincare LLC, and INNOVATIVE SKINCARE®

Sherry Goldman RN, NP, MSN | Manhattan Beach, CA
Nurse Practitioner at Cedars Sinai Breast Center in Los Angeles

Ira Hillman | Treasurer | New York, NY
Director Parenting and Early Childhood Portfolio, Einhorn Family Charitable Trust

Judi Hirshfield-Bartek, RN, MS, OCN | Waban, MA
Breast Cancer Advocate

Bryan Johns | Los Angeles, CA
Co-founder, President and CEO for Science of Skincare, LLC, and INNOVATIVE SKINCARE®

Liane Martins Lindner | Chair | New York, NY
Marketing and Communications Consultant

Nicole Maloney | Los Angeles, CA
Photographic Messaging Artist

Sharon Nelles, JD | New York, NY
Partner, Sullivan & Cromwell’s Litigation Group

Christine Norton, MA | Secretary | Cottage Grove, MN
Co-founder, Minnesota Breast Cancer Coalition and advocate reviewer for HealthNewsReview.org

Michele Rakoff | Beverly Hills, CA
Executive Director of Breast Cancer Care & Research Fund and Vice President of CABCIO
CA Teacher’s Study and the Love/Avon Army of Women Scientific Advisory Board

Linda Rothweiler, DMD | Vice Chair | Radnor, PA
Dentist and Breast Cancer Advocate

Dennis Slamon, MD, PhD | Woodland Hills, CA
Professor of Medicine, Chief of the Division of Hematology/Oncology; Executive Vice Chair for Research, Department of Medicine at UCLA; Director Clinical/Translational Research at the Jonsson Comprehensive Cancer Center; Director of Revlon/UCLA Women’s Cancer Research Program

Frances M. Visco, JD | Philadelphia, PA
President, National Breast Cancer Coalition (NBCC)

Carol Vance Wall | Montclair, New Jersey
Director, Vance Wall Foundation
The **National Breast Cancer Coalition Fund** is a 501 (c)(3) entity that designs and runs programs to educate, train, and inform advocates, policy makers, scientists, providers, and the public about science, health care and advocacy. The Fund collaborates with the research community on innovative research, effects change in the health care system to advance access to quality health care for all, and gives a powerful, effective voice to breast cancer advocates everywhere.

The **National Breast Cancer Coalition** is a 501 (c)(4) organization that designs and works to enact legislation, policy, and regulation to end breast cancer. The Coalition lobbies through its grassroots network for increased funding for innovative research, a seat at the table to oversee how those funds are spent, and public policies to expand access to quality health care for all.